Array Biopharma Stock Price, News & Analysis (NASDAQ:ARRY)

$18.15 +0.26 (+1.45 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$18.15
Today's Range$17.31 - $18.17
52-Week Range$6.73 - $18.30
Volume2.59 million shs
Average Volume4.86 million shs
Market Capitalization$3.63 billion
P/E Ratio-23.57
Dividend YieldN/A
Beta2.03

About Array Biopharma (NASDAQ:ARRY)

Array Biopharma logoArray BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.

Receive ARRY News and Ratings via Email

Sign-up to receive the latest news and ratings for ARRY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:ARRY
CUSIP04269X10
Phone+1-303-3816600

Debt

Debt-to-Equity Ratio0.39%
Current Ratio6.17%
Quick Ratio6.17%

Price-To-Earnings

Trailing P/E Ratio-23.5714285714286
Forward P/E Ratio-20.86
P/E GrowthN/A

Sales & Book Value

Annual Sales$150.85 million
Price / Sales24.98
Cash FlowN/A
Price / CashN/A
Book Value$1.17 per share
Price / Book15.51

Profitability

Trailing EPS($0.77)
Net Income$-116,810,000.00
Net Margins-98.51%
Return on Equity-107.79%
Return on Assets-36.51%

Miscellaneous

Employees209
Outstanding Shares207,640,000

Array Biopharma (NASDAQ:ARRY) Frequently Asked Questions

What is Array Biopharma's stock symbol?

Array Biopharma trades on the NASDAQ under the ticker symbol "ARRY."

How were Array Biopharma's earnings last quarter?

Array Biopharma Inc (NASDAQ:ARRY) released its earnings results on Tuesday, February, 6th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.23) by $0.06. The biopharmaceutical company had revenue of $42.21 million for the quarter, compared to analyst estimates of $26.81 million. Array Biopharma had a negative net margin of 98.51% and a negative return on equity of 107.79%. The firm's quarterly revenue was down 5.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.14) EPS. View Array Biopharma's Earnings History.

When will Array Biopharma make its next earnings announcement?

Array Biopharma is scheduled to release their next quarterly earnings announcement on Wednesday, May, 9th 2018. View Earnings Estimates for Array Biopharma.

Where is Array Biopharma's stock going? Where will Array Biopharma's stock price be in 2018?

8 brokerages have issued 1 year price targets for Array Biopharma's stock. Their predictions range from $13.00 to $23.00. On average, they anticipate Array Biopharma's share price to reach $17.25 in the next year. View Analyst Ratings for Array Biopharma.

What are Wall Street analysts saying about Array Biopharma stock?

Here are some recent quotes from research analysts about Array Biopharma stock:

  • 1. According to Zacks Investment Research, "Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company's proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. " (2/9/2018)
  • 2. Cantor Fitzgerald analysts commented, "ARRY and ASLAN (NC) have updated a 2011 agreement for varlitinib, a pan-HER2 inhibitor, providing nearer term cash to ARRY in exchange for commercialization rights (the prior agreement covered development)." (1/3/2018)
  • 3. Cowen Inc analysts commented, "We see ARRY's decision to withdraw the NRAS NDA as prudent given the known modest efficacy benefit. The NRAS-mutant melanoma opportunity represented a modest 6% of our base model DCF, thus we lower our PT modestly from $15 to $14. We view recent share weakness and the passing of this 'risk' event as an especially attractive opportunity to firmly reiterate our Outperform rating on ARRY shares." (3/20/2017)

Are investors shorting Array Biopharma?

Array Biopharma saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 13,249,317 shares, a drop of 15.4% from the January 12th total of 15,655,512 shares. Based on an average daily trading volume, of 5,295,563 shares, the days-to-cover ratio is presently 2.5 days. Currently, 6.8% of the company's shares are sold short.

Who are some of Array Biopharma's key competitors?

Who are Array Biopharma's key executives?

Array Biopharma's management team includes the folowing people:

  • Kyle A. Lefkoff, Independent Chairman of the Board (Age 56)
  • Ron R. Squarer, Chief Executive Officer, Director (Age 50)
  • Jason Haddock, Chief Financial Officer (Age 47)
  • Andrew R. Robbins, Chief Operating Officer (Age 41)
  • Nicholas A. Saccomano Ph.D., Chief Scientific Officer (Age 58)
  • Curtis Gale Oltmans, General Counsel (Age 54)
  • Victor Sandor, Chief Medical Officer (Age 51)
  • Shalini Sharp, Director (Age 42)
  • Charles M. Baum M.D., Ph.D., Independent Director (Age 59)
  • Gwendolyn A. Fyfe M.D., Independent Director (Age 65)

Who owns Array Biopharma stock?

Array Biopharma's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.35%), Franklin Resources Inc. (4.42%), BVF Inc. IL (4.18%), Millennium Management LLC (1.35%), Pinnacle Associates Ltd. (1.31%) and Driehaus Capital Management LLC (1.21%). Company insiders that own Array Biopharma stock include Andrew R Robbins, Charles M Baum, Jason Haddock, Kyle Lefkoff, Lunsen Gil J Van, Redmile Group, Llc and Ron Squarer. View Institutional Ownership Trends for Array Biopharma.

Who sold Array Biopharma stock? Who is selling Array Biopharma stock?

Array Biopharma's stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Pinnacle Associates Ltd., Goldman Sachs Group Inc., Candriam Luxembourg S.C.A., Wells Fargo & Company MN, Two Sigma Advisers LP, Millennium Management LLC and Cambiar Investors LLC. Company insiders that have sold Array Biopharma company stock in the last year include Andrew R Robbins, Charles M Baum, Jason Haddock, Kyle Lefkoff, Lunsen Gil J Van and Ron Squarer. View Insider Buying and Selling for Array Biopharma.

Who bought Array Biopharma stock? Who is buying Array Biopharma stock?

Array Biopharma's stock was purchased by a variety of institutional investors in the last quarter, including BVF Inc. IL, BlackRock Inc., UBS Asset Management Americas Inc., Eversept Partners LLC, Franklin Resources Inc., Renaissance Technologies LLC, Handelsbanken Fonder AB and Driehaus Capital Management LLC. View Insider Buying and Selling for Array Biopharma.

How do I buy Array Biopharma stock?

Shares of Array Biopharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Array Biopharma's stock price today?

One share of Array Biopharma stock can currently be purchased for approximately $18.15.

How big of a company is Array Biopharma?

Array Biopharma has a market capitalization of $3.63 billion and generates $150.85 million in revenue each year. The biopharmaceutical company earns $-116,810,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis. Array Biopharma employs 209 workers across the globe.

How can I contact Array Biopharma?

Array Biopharma's mailing address is 3200 Walnut St, BOULDER, CO 80301-2514, United States. The biopharmaceutical company can be reached via phone at +1-303-3816600 or via email at [email protected]


MarketBeat Community Rating for Array Biopharma (ARRY)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  325 (Vote Outperform)
Underperform Votes:  165 (Vote Underperform)
Total Votes:  490
MarketBeat's community ratings are surveys of what our community members think about Array Biopharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Array Biopharma (NASDAQ:ARRY) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.002.882.86
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $17.25$15.25$14.13$12.00
Price Target Upside: 1.71% downside16.06% upside35.17% upside30.15% upside

Array Biopharma (NASDAQ:ARRY) Consensus Price Target History

Price Target History for Array Biopharma (NASDAQ:ARRY)

Array Biopharma (NASDAQ:ARRY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/7/2018Leerink SwannBoost Price TargetOutperform -> Outperform$19.00 -> $20.00LowView Rating Details
2/7/2018Stifel NicolausBoost Price TargetBuy -> Buy$20.00 -> $23.00HighView Rating Details
2/6/2018SunTrust BanksReiterated RatingBuy$20.00LowView Rating Details
1/21/2018Cantor FitzgeraldReiterated RatingBuy$15.00LowView Rating Details
12/22/2017Jefferies GroupBoost Price TargetBuy$13.00N/AView Rating Details
9/20/2017Piper Jaffray CompaniesReiterated RatingOverweight$14.00 -> $18.00LowView Rating Details
9/11/2017CowenReiterated RatingOutperform$14.00 -> $15.00HighView Rating Details
9/11/2017JPMorgan Chase & Co.Reiterated RatingBuy$14.00HighView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Array Biopharma (NASDAQ:ARRY) Earnings History and Estimates Chart

Earnings by Quarter for Array Biopharma (NASDAQ:ARRY)

Array Biopharma (NASDAQ ARRY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018($0.22)N/AView Earnings Details
2/6/2018Q2 2018($0.23)($0.17)$26.81 million$42.21 millionViewN/AView Earnings Details
10/31/2017Q1 2018($0.22)($0.22)$33.74 million$29.75 millionViewN/AView Earnings Details
8/9/2017Q4 2017($0.21)($0.17)$28.64 million$33.80 millionViewListenView Earnings Details
5/10/2017Q3 2017($0.16)($0.21)$38.28 million$33.28 millionViewN/AView Earnings Details
2/9/2017Q2 2017($0.18)($0.14)$31.90 million$44.50 millionViewListenView Earnings Details
11/1/2016Q117($0.16)($0.20)$32.47 million$39.30 millionViewListenView Earnings Details
8/4/2016Q416($0.14)($0.17)$41.51 million$43.20 millionViewListenView Earnings Details
5/3/2016Q316($0.12)($0.16)$30.35 million$43.00 millionViewListenView Earnings Details
2/2/2016Q216($0.06)($0.17)$32.70 million$35.40 millionViewListenView Earnings Details
11/4/2015Q116($0.18)($0.15)$14.02 million$16.20 millionViewListenView Earnings Details
8/3/2015Q415($0.16)($0.09)$10.29 million$12.30 millionViewListenView Earnings Details
5/4/2015Q315($0.01)$0.37$6.00 million$6.60 millionViewListenView Earnings Details
2/3/2015Q215($0.20)($0.06)$10.20 million$26.92 millionViewListenView Earnings Details
11/4/2014Q115($0.22)($0.21)$6.35 million$6.07 millionViewListenView Earnings Details
8/12/2014Q414($0.23)($0.22)$8.10 million$6.00 millionViewListenView Earnings Details
4/29/2014Q314($0.21)($0.20)$9.40 million$7.80 millionViewListenView Earnings Details
2/4/2014Q214($0.16)($0.13)$13.49 million$14.10 millionViewListenView Earnings Details
10/31/2013Q114($0.18)($0.13)$11.20 million$14.20 millionViewListenView Earnings Details
8/7/2013Q4 2013($0.13)($0.06)$16.13 million$25.40 millionViewListenView Earnings Details
5/6/2013Q3 2013($0.14)($0.19)$14.54 million$10.00 millionViewListenView Earnings Details
2/4/2013Q2 2013($0.14)($0.10)$16.52 million$18.40 millionViewListenView Earnings Details
10/29/2012Q113($0.15)($0.13)$16.70 million$15.80 millionViewN/AView Earnings Details
8/13/2012($0.11)($0.09)ViewN/AView Earnings Details
4/30/2012($0.16)($0.11)ViewN/AView Earnings Details
1/30/2012($0.12)($0.06)ViewN/AView Earnings Details
10/31/2011Q1 2012($0.19)($0.06)ViewN/AView Earnings Details
8/8/2011Q4 2011($0.27)($0.17)ViewN/AView Earnings Details
5/2/2011($0.25)($0.20)ViewN/AView Earnings Details
1/31/2011($0.28)($0.23)ViewN/AView Earnings Details
11/8/2010Q1 2011($0.28)($0.20)ViewN/AView Earnings Details
8/9/2010Q4 2010($0.32)($0.30)ViewN/AView Earnings Details
5/3/2010Q3 2010($0.34)($0.30)ViewN/AView Earnings Details
2/1/2010Q2 2010($0.55)($0.44)ViewN/AView Earnings Details
11/2/2009Q1 2010($0.55)($0.52)ViewN/AView Earnings Details
8/10/2009Q4 2009($0.55)($0.55)ViewN/AView Earnings Details
5/4/2009Q3 2009($0.58)($0.55)ViewN/AView Earnings Details
2/2/2009Q2 2009($0.65)($0.57)ViewN/AView Earnings Details
11/3/2008Q1 2009($0.65)($0.63)ViewN/AView Earnings Details
8/11/2008Q4 2008($0.63)($0.68)ViewN/AView Earnings Details
5/5/2008Q3 2008($0.51)($0.51)ViewN/AView Earnings Details
2/4/2008Q2 2008($0.46)($0.43)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Array Biopharma (NASDAQ:ARRY) Earnings Estimates

2018 EPS Consensus Estimate: ($0.97)
2019 EPS Consensus Estimate: ($0.71)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.31)($0.19)($0.25)
Q2 20182($0.32)($0.18)($0.25)
Q3 20183($0.27)($0.18)($0.21)
Q4 20183($0.29)($0.21)($0.26)
Q1 20191($0.24)($0.24)($0.24)
Q2 20191($0.01)($0.01)($0.01)
Q3 20191($0.23)($0.23)($0.23)
Q4 20191($0.23)($0.23)($0.23)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Array Biopharma (NASDAQ:ARRY)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Array Biopharma (NASDAQ ARRY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.18%
Institutional Ownership Percentage: 94.02%
Insider Trades by Quarter for Array Biopharma (NASDAQ:ARRY)
Institutional Ownership by Quarter for Array Biopharma (NASDAQ:ARRY)

Array Biopharma (NASDAQ ARRY) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/21/2018Lunsen Gil J VanDirectorSell21,500$17.16$368,940.0032,797View SEC Filing  
2/9/2018Charles M BaumDirectorSell50,000$16.90$845,000.0035,000View SEC Filing  
1/17/2018Lunsen Gil J VanDirectorSell21,500$12.94$278,210.0034,297View SEC Filing  
1/16/2018Jason HaddockCFOSell7,500$13.73$102,975.0036,368View SEC Filing  
12/19/2017Ron SquarerCEOSell819,671$10.86$8,901,627.06View SEC Filing  
12/18/2017Andrew R. RobbinsCOOSell282,874$10.72$3,032,409.28View SEC Filing  
9/29/2017Kyle LefkoffDirectorSell38,865$12.31$478,428.1551,585View SEC Filing  
3/28/2017Charles M BaumDirectorSell25,000$9.27$231,750.0030,000View SEC Filing  
9/28/2016Redmile Group, LlcMajor ShareholderSell2,492,578$6.36$15,852,796.08View SEC Filing  
9/15/2016Redmile Group, LlcMajor ShareholderBuy400,000$3.51$1,404,000.00View SEC Filing  
1/20/2016Redmile Group, LlcMajor ShareholderBuy300,000$3.19$957,000.00View SEC Filing  
1/12/2016Redmile Group, LlcMajor ShareholderBuy75,000$3.60$270,000.00View SEC Filing  
1/11/2016Redmile Group, LlcMajor ShareholderBuy925,000$3.67$3,394,750.00View SEC Filing  
10/1/2015Redmile Group, LlcMajor ShareholderBuy782,592$4.58$3,584,271.36View SEC Filing  
8/25/2015Redmile Group, LlcMajor ShareholderBuy790,000$5.38$4,250,200.00View SEC Filing  
8/10/2015Redmile Group, LlcMajor ShareholderBuy1,048,993$5.80$6,084,159.40View SEC Filing  
3/3/2015Kyle LefkoffDirectorSell70,000$8.00$560,000.00View SEC Filing  
3/2/2015Andrews R RobbinsSVPSell21,576$8.25$178,002.00View SEC Filing  
3/2/2015Ron SquarerCEOSell40,000$8.25$330,000.00View SEC Filing  
9/16/2013Liam RatcliffeDirectorSell1,673,172$6.08$10,172,885.76View SEC Filing  
9/6/2013Liam RatcliffeDirectorSell577,286$5.79$3,342,485.94View SEC Filing  
8/2/2013John R MooreVPSell75,384$7.02$529,195.68View SEC Filing  
7/23/2013John R MooreVPSell5,000$6.50$32,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Array Biopharma (NASDAQ ARRY) News Headlines

Source:
DateHeadline
Array Biopharma Inc (ARRY) Director Sells $368,940.00 in StockArray Biopharma Inc (ARRY) Director Sells $368,940.00 in Stock
www.americanbankingnews.com - February 23 at 6:32 PM
Array BioPharma Inc. (ARRY) Given Average Rating of "Buy" by BrokeragesArray BioPharma Inc. (ARRY) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 21 at 10:50 AM
Array BioPharma (ARRY) Price Target Raised to $20.00Array BioPharma (ARRY) Price Target Raised to $20.00
www.americanbankingnews.com - February 19 at 9:40 PM
Options Traders Expect Huge Moves in Array BioPharma (ARRY) StockOptions Traders Expect Huge Moves in Array BioPharma (ARRY) Stock
finance.yahoo.com - February 16 at 9:30 AM
Zacks.com highlights: Cinemark Holdings, Hasbro, Enova International, Array BioPharma and TechTargetZacks.com highlights: Cinemark Holdings, Hasbro, Enova International, Array BioPharma and TechTarget
finance.yahoo.com - February 14 at 3:22 PM
Array BioPharma Inc. (ARRY) Director Charles M. Baum Sells 50,000 SharesArray BioPharma Inc. (ARRY) Director Charles M. Baum Sells 50,000 Shares
www.americanbankingnews.com - February 12 at 6:32 PM
$31.65 Million in Sales Expected for Array BioPharma Inc. (ARRY) This Quarter$31.65 Million in Sales Expected for Array BioPharma Inc. (ARRY) This Quarter
www.americanbankingnews.com - February 12 at 6:18 AM
Zacks: Brokerages Anticipate Array BioPharma Inc. (ARRY) to Announce -$0.22 EPSZacks: Brokerages Anticipate Array BioPharma Inc. (ARRY) to Announce -$0.22 EPS
www.americanbankingnews.com - February 10 at 9:44 AM
Short Interest in Array BioPharma Inc. (ARRY) Decreases By 15.4%Short Interest in Array BioPharma Inc. (ARRY) Decreases By 15.4%
www.americanbankingnews.com - February 10 at 2:02 AM
Array BioPharma (ARRY) Stock Rating Upgraded by Zacks Investment ResearchArray BioPharma (ARRY) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - February 9 at 6:10 PM
Q3 2018 Earnings Forecast for Array BioPharma Inc. Issued By Leerink Swann (ARRY)Q3 2018 Earnings Forecast for Array BioPharma Inc. Issued By Leerink Swann (ARRY)
www.americanbankingnews.com - February 9 at 11:36 AM
Array BioPharma Inc. (ARRY) Forecasted to Post Q3 2018 Earnings of ($0.27) Per ShareArray BioPharma Inc. (ARRY) Forecasted to Post Q3 2018 Earnings of ($0.27) Per Share
www.americanbankingnews.com - February 9 at 11:36 AM
FY2022 Earnings Forecast for Array BioPharma Inc. Issued By SunTrust Banks (ARRY)FY2022 Earnings Forecast for Array BioPharma Inc. Issued By SunTrust Banks (ARRY)
www.americanbankingnews.com - February 8 at 5:52 PM
Leerink Swann Comments on Array BioPharma Inc.s Q1 2019 Earnings (ARRY)Leerink Swann Comments on Array BioPharma Inc.'s Q1 2019 Earnings (ARRY)
www.americanbankingnews.com - February 8 at 3:52 PM
Heres Why Array BioPharma Inc. Is Rising Today - Motley FoolHere's Why Array BioPharma Inc. Is Rising Today - Motley Fool
www.fool.com - February 8 at 3:20 PM
Array BioPharma To Present At The LEERINK Partners 7th Annual Global Healthcare ConferenceArray BioPharma To Present At The LEERINK Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 8 at 5:48 AM
Arrays Melanoma Combo Shows Positive Overall Survival DataArray's Melanoma Combo Shows Positive Overall Survival Data
feeds.benzinga.com - February 7 at 12:04 PM
Array BioPharma (ARRY) PT Raised to $23.00 at Stifel NicolausArray BioPharma (ARRY) PT Raised to $23.00 at Stifel Nicolaus
www.americanbankingnews.com - February 7 at 9:52 AM
Here's Why Array BioPharma Inc. Is Rising TodayHere's Why Array BioPharma Inc. Is Rising Today
finance.yahoo.com - February 7 at 5:58 AM
Array BioPharma (ARRY) Stock Rating Reaffirmed by SunTrust BanksArray BioPharma (ARRY) Stock Rating Reaffirmed by SunTrust Banks
www.americanbankingnews.com - February 6 at 4:06 PM
Array BioPharma Announces Results Of Phase 3 COLUMBUS Trial - NasdaqArray BioPharma Announces Results Of Phase 3 COLUMBUS Trial - Nasdaq
www.nasdaq.com - February 6 at 3:20 PM
Does Array BioPharma Inc’s (NASDAQ:ARRY) Debt Level Pose A Problem?Does Array BioPharma Inc’s (NASDAQ:ARRY) Debt Level Pose A Problem?
finance.yahoo.com - February 6 at 3:20 PM
Array BioPharma (ARRY) Posts  Earnings Results, Beats Estimates By $0.06 EPSArray BioPharma (ARRY) Posts Earnings Results, Beats Estimates By $0.06 EPS
www.americanbankingnews.com - February 6 at 11:14 AM
Today’s Research Reports on Trending Tickers: Array BioPharma and TG TherapeuticsToday’s Research Reports on Trending Tickers: Array BioPharma and TG Therapeutics
finance.yahoo.com - February 5 at 3:19 PM
AstraZeneca is sued by Array BioPharma over cancer drug royaltiesAstraZeneca is sued by Array BioPharma over cancer drug royalties
finance.yahoo.com - February 2 at 5:49 AM
PRESS DIGEST- British Business - Feb 2PRESS DIGEST- British Business - Feb 2
finance.yahoo.com - February 2 at 5:49 AM
Array BioPharma’s Financial PerformanceArray BioPharma’s Financial Performance
finance.yahoo.com - January 31 at 3:19 PM
Array BioPharma’s ARRY-382 and ARRY-797Array BioPharma’s ARRY-382 and ARRY-797
finance.yahoo.com - January 31 at 3:19 PM
An In-Depth Look at Array BioPharma’s Pipeline of DrugsAn In-Depth Look at Array BioPharma’s Pipeline of Drugs
finance.yahoo.com - January 31 at 5:58 AM
Array BioPharma (ARRY) to Release Quarterly Earnings on WednesdayArray BioPharma (ARRY) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - January 31 at 2:10 AM
Array BioPharma To Report Financial Results For The Second Quarter Of Fiscal 2018 On February 6, 2018Array BioPharma To Report Financial Results For The Second Quarter Of Fiscal 2018 On February 6, 2018
finance.yahoo.com - January 30 at 3:19 PM
Array BioPharma Inc. (ARRY) Receives Average Recommendation of "Buy" from AnalystsArray BioPharma Inc. (ARRY) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 27 at 10:32 AM
 Brokerages Anticipate Array BioPharma Inc. (ARRY) Will Post Quarterly Sales of $24.82 Million Brokerages Anticipate Array BioPharma Inc. (ARRY) Will Post Quarterly Sales of $24.82 Million
www.americanbankingnews.com - January 26 at 6:46 AM
Mylan CEO: I'm excited about our pipelineMylan CEO: I'm excited about our pipeline
finance.yahoo.com - January 25 at 3:20 PM
Taking Stock of Radius Health’s Licensing AgreementsTaking Stock of Radius Health’s Licensing Agreements
finance.yahoo.com - January 25 at 3:20 PM
Q3 2018 EPS Estimates for Array BioPharma Inc. Raised by Leerink Swann (ARRY)Q3 2018 EPS Estimates for Array BioPharma Inc. Raised by Leerink Swann (ARRY)
www.americanbankingnews.com - January 24 at 1:56 PM
Zacks: Analysts Anticipate Array BioPharma Inc. (ARRY) to Announce -$0.23 EPSZacks: Analysts Anticipate Array BioPharma Inc. (ARRY) to Announce -$0.23 EPS
www.americanbankingnews.com - January 24 at 11:18 AM
Array Biopharma (ARRY) Reports Updated Results for Phase 3 BEACON CRC Trial Evaluating Triplet Combination of ... - StreetInsider.comArray Biopharma (ARRY) Reports Updated Results for Phase 3 BEACON CRC Trial Evaluating Triplet Combination of ... - StreetInsider.com
www.streetinsider.com - January 23 at 3:23 PM
Why Array BioPharma Inc. Is Soaring - Motley FoolWhy Array BioPharma Inc. Is Soaring - Motley Fool
www.fool.com - January 23 at 3:23 PM
DEADLINE ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint on Behalf of Array Biopharma Inc. Shareholders and Lead Plaintiff Deadline of January 22, 2018 - ARRYDEADLINE ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint on Behalf of Array Biopharma Inc. Shareholders and Lead Plaintiff Deadline of January 22, 2018 - ARRY
finance.yahoo.com - January 23 at 9:18 AM
FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Array Biopharma, Inc. (ARRY) & Lead Plaintiff Deadline: January 22, 2018FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Array Biopharma, Inc. (ARRY) & Lead Plaintiff Deadline: January 22, 2018
finance.yahoo.com - January 23 at 9:18 AM
Today’s Research Reports on Stocks to Watch: Array BioPharma and Sorrento TherapeuticsToday’s Research Reports on Stocks to Watch: Array BioPharma and Sorrento Therapeutics
finance.yahoo.com - January 23 at 9:18 AM
Cantor Fitzgerald Reaffirms "Buy" Rating for Array BioPharma (ARRY)Cantor Fitzgerald Reaffirms "Buy" Rating for Array BioPharma (ARRY)
www.americanbankingnews.com - January 22 at 10:34 PM
Pre-Open Movers 01/22: (BIVV) (JUNO) (ARRY) Higher; (SANM) (TEVA) (TWTR) Lower (more...) - StreetInsider.comPre-Open Movers 01/22: (BIVV) (JUNO) (ARRY) Higher; (SANM) (TEVA) (TWTR) Lower (more...) - StreetInsider.com
www.streetinsider.com - January 22 at 3:23 PM
Why Array BioPharma Inc. Is SoaringWhy Array BioPharma Inc. Is Soaring
www.fool.com - January 22 at 12:33 PM
Stifel Nicolaus Boosts Array BioPharma (ARRY) Price Target to $20.00Stifel Nicolaus Boosts Array BioPharma (ARRY) Price Target to $20.00
www.americanbankingnews.com - January 22 at 8:00 AM
Combination of Encorafenib, Binimetinib and Cetuximab Demonstrated an 8 Month Median Progression-Free Survival in BRAF-Mutant Colorectal Cancer in Updated Safety Lead-In Results from BEACON Phase 3 TrialCombination of Encorafenib, Binimetinib and Cetuximab Demonstrated an 8 Month Median Progression-Free Survival in BRAF-Mutant Colorectal Cancer in Updated Safety Lead-In Results from BEACON Phase 3 Trial
www.prnewswire.com - January 20 at 12:10 PM
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Array Biopharma, Inc. (ARRY) & Lead Plaintiff Deadline - January 22, 2018DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Array Biopharma, Inc. (ARRY) & Lead Plaintiff Deadline - January 22, 2018
finance.yahoo.com - January 18 at 3:22 PM
ARRY EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Array Biopharma Inc. and a Lead Plaintiff Deadline of January 22, 2018ARRY EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Array Biopharma Inc. and a Lead Plaintiff Deadline of January 22, 2018
finance.yahoo.com - January 18 at 3:22 PM
Lunsen Gil J. Van Sells 21,500 Shares of Array BioPharma Inc. (ARRY) StockLunsen Gil J. Van Sells 21,500 Shares of Array BioPharma Inc. (ARRY) Stock
www.americanbankingnews.com - January 17 at 7:04 PM

SEC Filings

Array Biopharma (NASDAQ:ARRY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Array Biopharma (NASDAQ:ARRY) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Array Biopharma (NASDAQ ARRY) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.